Latest Gynecologic oncology Stories
Many women who survive breast and gynecologic cancers want medical help for their sexual issues, but most do not get it. A survey of hundreds of cancer survivors, published online in the journal Cancer, confirms that more than forty percent want medical attention for their sexual health needs."Some women have the courage to raise sexual concerns with their doctor, although repeated studies show they prefer the doctor to initiate the discussion," said Stacy Tessler Lindau, MD,...
Research by the American Academy of Family Physicians demonstrates that vulvar cancer occurs most frequently in women age 65 to 75 years of age. Thirty percent of patients with vulvar cancer are age 70 or older, and the rate increases with age, reaching a peak of 20 per 100,000 women by 75 years of age.A team of researchers headed by Ashley Stuckey, MD, and Don Dizon, MD, of the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, recently presented research to the...
CHICAGO, Jan. 24, 2011 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) will host its 42nd Annual Meeting on Women's Cancer March 6-9, 2011, at the Hilton Bonnet Creek & Waldorf Astoria Orlando in Orlando, Florida. This year's meeting will feature 278 scientific presentations in addition to lectures, workshops, symposia and postgraduate courses that focus on emerging science, clinical trials and treatment advances for physicians and health care professionals in...
Women's Oncology Research & Dialogue (WORD) urges women to take action and protect themselves in the new year against cervical cancer and HPV during Cervical Health Awareness Month. WORD has launched "WORD on HPV" health education campaign including a four-minute animated short, posters, brochures, rack cards, informative videos and more to help raise awareness of HPV and cervical cancer.Indianapolis, IN (PRWEB) January 13, 2011 This year, Over 11,000 American women will learn...
Virtually eliminates need for narcotic painkillers, cuts hospital staysRobot-assisted surgery dramatically improves outcomes in patients with uterine, endometrial, and cervical cancer, said researchers at the Jewish General Hospital's Lady Davis Institute for Medical Research in Montreal. Moreover, because of fewer post-operative complications and shorter hospital stays, robotic procedures also cost less.These results were published in late 2010 in a series of studies in The Journal of...
Cancer prevention experts have long been frustrated by the lack of a meaningful way to screen women for ovarian cancer. It is a relatively rare disease that often progresses with few symptoms until it is too late for potentially curative treatments, and elevated values of the most commonly used biomarker used in screening, CA125, are also related to other disorders.Now, scientists at the Duke Cancer Institute say that incorporating the latest information about the biological diversity of...
HUNTSVILLE, Ala., Dec. 13, 2010 /PRNewswire/ -- EGEN, Inc. today announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment. The trial is sponsored by the Gynecologic Oncology Group (GOG) under an agreement between the GOG and EGEN, Inc., and is being conducted by a network of researchers led by the GOG at member institutions. The University of Alabama at Birmingham (UAB) Hospital is the first member...
QUEBEC, Dec. 7 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS,TSX:Â AEZ) (the "Company") will hold an R&D Review for investors and analysts on Tuesday, December 14, 2010 from 4 p.m. to 6 p.m. (EST) in the Park Avenue Room of the InterContinental New York Barclay Hotel in New York City. Aeterna Zentaris' management will introduce the Company's robust pipeline, focused mainly on oncology, and will be available for further discussion. Detailed presentations of the Company's...
CALGARY, Dec. 1 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN((R)) in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study is being sponsored by the Cancer Therapy...
Women's Oncology Research & Dialogue has lanched a new website to inform women about ovarian, uterine, cervical and all gynecologic cancers at wordoncancer.org. Indianapolis, IN (PRWEB) November 9, 2010 On November 9, 2010 Women's Oncology Research & Dialogue launched their new website at http://www.wordoncancer.org. WORD was founded with the mission of spreading awareness as well as offering insight and education on gynecologic cancers to the world. Founded by two gynecologic...
